{"commentary":{"count":41,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":24,"podcast":9,"youtube":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03498716\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IMpassion030","nct_id":"NCT03498716","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=impassion030-nct03498716. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"IMpassion030","arms":[{"description":"Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose\n\nChemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)","label":"Atezolizumab + Chemotherapy","type":"EXPERIMENTAL"},{"description":"Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)","label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Breast International Group","Alliance Foundation Trials, LLC.","Jules Bordet Institute","Frontier Science & Technology Research Foundation, Inc."],"completion_date":{"date":"2023-08-14","type":"ACTUAL"},"conditions":["Triple Negative Breast Cancer"],"enrollment":{"count":2199,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Dose-dense Doxorubicin or dose-dense Epirubicin","type":"DRUG"},{"name":"Cyclophosphamide","type":"DRUG"}],"last_update":"2024-08-21","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Invasive Disease-Free Survival (iDFS)","timeFrame":"From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years)"}],"references":[{"citation":"Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, Chui SY, Dieterich M, Perretti T, Shearer-Kang E, Molinero L, Steger GG, Jassem J, Lee SC, Higgins M, Zarba J, Schmidt M, Gomez H, Guerrero Zotano A, Moscetti L, Chiu J, Munzone E, Ben-Baruch NE, Bajetta E, Ohno S, Im SA, Werutsky G, Gal-Yam EN, Gonzalez Farre X, Tseng LM, Jacot W, Gluz O, Shao Z, Shparyk Y, Zimina A, Winer E, Cameron DA, Viale G, Saji S, Gelber R, Piccart M. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial. JAMA. 2025 Jan 30;333(13):1150-60. doi: 10.1001/jama.2024.26886. Online ahead of print.","pmid":"39883436","type":"DERIVED"},{"citation":"Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25.","pmid":"32450725","type":"DERIVED"}],"start_date":{"date":"2018-08-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT03498716"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/impassion030-nct03498716"}